Virological and immunological characterization of novel NYVAC-Based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles

Beatriz Perdiguero, Carmen Elena Gómez, Victoria Cepeda, Lucas Sánchez-Sampedro, Juan García-Arriaza, Ernesto Mejías-Pérez, Victoria Jiménez, Cristina Sánchez, Carlos Óscar S Sorzano, Juan Carlos Oliveros, Julie Delaloye, Thierry Roger, Thierry Calandra, Benedikt Asbach, Ralf Wagner, Karen Kibler, Bertram Jacobs, Giuseppe Pantaleo, Mariano Esteban

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The generation of vaccines against HIV/AIDS able to induce long-lasting protective immunity remains a major goal in the HIV field. The modest efficacy (31.2%) against HIV infection observed in the RV144 phase III clinical trial highlighted the need for further improvement of HIV vaccine candidates, formulation, and vaccine regimen. In this study, we have generated two novel NYVAC vectors, expressing HIV-1 clade C gp140(ZM96) (NYVAC-gp140) or Gag(ZM96)-Pol-Nef(CN54) (NYVAC-Gag-Pol- Nef), and defined their virological and immunological characteristics in cultured cells and in mice. The insertion of HIV genes does not affect the replication capacity of NYVAC recombinants in primary chicken embryo fibroblast cells, HIV sequences remain stable after multiple passages, and HIV antigens are correctly expressed and released from cells, with Env as a trimer (NYVAC-gp140), while in NYVAC-Gag-Pol-Nef-infected cells Gag-induced virus-like particles (VLPs) are abundant. Electron microscopy revealed that VLPs accumulated with time at the cell surface, with no interference with NYVAC morphogenesis. Both vectors trigger specific innate responses in human cells and show an attenuation profile in immunocompromised adult BALB/c and newborn CD1 mice after intracranial inoculation. Analysis of the immune responses elicited in mice after homologous NYVAC prime/NYVAC boost immunization shows that recombinant viruses induced polyfunctional Env-specific CD4 or Gag-specific CD8 T cell responses. Antibody responses against gp140 and p17/p24 were elicited. Our findings showed important insights into virus-host cell interactions of NYVAC vectors expressing HIV antigens, with the activation of specific immune parameters which will help to unravel potential correlates of protection against HIV in human clinical trials with these vectors.

Original languageEnglish (US)
Pages (from-to)970-988
Number of pages19
JournalJournal of Virology
Volume89
Issue number2
DOIs
StatePublished - 2015

Fingerprint

AIDS Vaccines
virus-like particles
Virion
vaccines
HIV Antigens
HIV
cells
clinical trials
mice
Viruses
antigens
viruses
Phase III Clinical Trials
Insertional Mutagenesis
HIV infections
Human immunodeficiency virus 1
crossover interference
Morphogenesis
Cell Communication
cultured cells

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Virological and immunological characterization of novel NYVAC-Based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles. / Perdiguero, Beatriz; Gómez, Carmen Elena; Cepeda, Victoria; Sánchez-Sampedro, Lucas; García-Arriaza, Juan; Mejías-Pérez, Ernesto; Jiménez, Victoria; Sánchez, Cristina; Sorzano, Carlos Óscar S; Oliveros, Juan Carlos; Delaloye, Julie; Roger, Thierry; Calandra, Thierry; Asbach, Benedikt; Wagner, Ralf; Kibler, Karen; Jacobs, Bertram; Pantaleo, Giuseppe; Esteban, Mariano.

In: Journal of Virology, Vol. 89, No. 2, 2015, p. 970-988.

Research output: Contribution to journalArticle

Perdiguero, B, Gómez, CE, Cepeda, V, Sánchez-Sampedro, L, García-Arriaza, J, Mejías-Pérez, E, Jiménez, V, Sánchez, C, Sorzano, CÓS, Oliveros, JC, Delaloye, J, Roger, T, Calandra, T, Asbach, B, Wagner, R, Kibler, K, Jacobs, B, Pantaleo, G & Esteban, M 2015, 'Virological and immunological characterization of novel NYVAC-Based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles', Journal of Virology, vol. 89, no. 2, pp. 970-988. https://doi.org/10.1128/JVI.02469-14
Perdiguero, Beatriz ; Gómez, Carmen Elena ; Cepeda, Victoria ; Sánchez-Sampedro, Lucas ; García-Arriaza, Juan ; Mejías-Pérez, Ernesto ; Jiménez, Victoria ; Sánchez, Cristina ; Sorzano, Carlos Óscar S ; Oliveros, Juan Carlos ; Delaloye, Julie ; Roger, Thierry ; Calandra, Thierry ; Asbach, Benedikt ; Wagner, Ralf ; Kibler, Karen ; Jacobs, Bertram ; Pantaleo, Giuseppe ; Esteban, Mariano. / Virological and immunological characterization of novel NYVAC-Based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles. In: Journal of Virology. 2015 ; Vol. 89, No. 2. pp. 970-988.
@article{8303d609d5eb4986869bfd19f06b77ee,
title = "Virological and immunological characterization of novel NYVAC-Based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles",
abstract = "The generation of vaccines against HIV/AIDS able to induce long-lasting protective immunity remains a major goal in the HIV field. The modest efficacy (31.2{\%}) against HIV infection observed in the RV144 phase III clinical trial highlighted the need for further improvement of HIV vaccine candidates, formulation, and vaccine regimen. In this study, we have generated two novel NYVAC vectors, expressing HIV-1 clade C gp140(ZM96) (NYVAC-gp140) or Gag(ZM96)-Pol-Nef(CN54) (NYVAC-Gag-Pol- Nef), and defined their virological and immunological characteristics in cultured cells and in mice. The insertion of HIV genes does not affect the replication capacity of NYVAC recombinants in primary chicken embryo fibroblast cells, HIV sequences remain stable after multiple passages, and HIV antigens are correctly expressed and released from cells, with Env as a trimer (NYVAC-gp140), while in NYVAC-Gag-Pol-Nef-infected cells Gag-induced virus-like particles (VLPs) are abundant. Electron microscopy revealed that VLPs accumulated with time at the cell surface, with no interference with NYVAC morphogenesis. Both vectors trigger specific innate responses in human cells and show an attenuation profile in immunocompromised adult BALB/c and newborn CD1 mice after intracranial inoculation. Analysis of the immune responses elicited in mice after homologous NYVAC prime/NYVAC boost immunization shows that recombinant viruses induced polyfunctional Env-specific CD4 or Gag-specific CD8 T cell responses. Antibody responses against gp140 and p17/p24 were elicited. Our findings showed important insights into virus-host cell interactions of NYVAC vectors expressing HIV antigens, with the activation of specific immune parameters which will help to unravel potential correlates of protection against HIV in human clinical trials with these vectors.",
author = "Beatriz Perdiguero and G{\'o}mez, {Carmen Elena} and Victoria Cepeda and Lucas S{\'a}nchez-Sampedro and Juan Garc{\'i}a-Arriaza and Ernesto Mej{\'i}as-P{\'e}rez and Victoria Jim{\'e}nez and Cristina S{\'a}nchez and Sorzano, {Carlos {\'O}scar S} and Oliveros, {Juan Carlos} and Julie Delaloye and Thierry Roger and Thierry Calandra and Benedikt Asbach and Ralf Wagner and Karen Kibler and Bertram Jacobs and Giuseppe Pantaleo and Mariano Esteban",
year = "2015",
doi = "10.1128/JVI.02469-14",
language = "English (US)",
volume = "89",
pages = "970--988",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "2",

}

TY - JOUR

T1 - Virological and immunological characterization of novel NYVAC-Based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles

AU - Perdiguero, Beatriz

AU - Gómez, Carmen Elena

AU - Cepeda, Victoria

AU - Sánchez-Sampedro, Lucas

AU - García-Arriaza, Juan

AU - Mejías-Pérez, Ernesto

AU - Jiménez, Victoria

AU - Sánchez, Cristina

AU - Sorzano, Carlos Óscar S

AU - Oliveros, Juan Carlos

AU - Delaloye, Julie

AU - Roger, Thierry

AU - Calandra, Thierry

AU - Asbach, Benedikt

AU - Wagner, Ralf

AU - Kibler, Karen

AU - Jacobs, Bertram

AU - Pantaleo, Giuseppe

AU - Esteban, Mariano

PY - 2015

Y1 - 2015

N2 - The generation of vaccines against HIV/AIDS able to induce long-lasting protective immunity remains a major goal in the HIV field. The modest efficacy (31.2%) against HIV infection observed in the RV144 phase III clinical trial highlighted the need for further improvement of HIV vaccine candidates, formulation, and vaccine regimen. In this study, we have generated two novel NYVAC vectors, expressing HIV-1 clade C gp140(ZM96) (NYVAC-gp140) or Gag(ZM96)-Pol-Nef(CN54) (NYVAC-Gag-Pol- Nef), and defined their virological and immunological characteristics in cultured cells and in mice. The insertion of HIV genes does not affect the replication capacity of NYVAC recombinants in primary chicken embryo fibroblast cells, HIV sequences remain stable after multiple passages, and HIV antigens are correctly expressed and released from cells, with Env as a trimer (NYVAC-gp140), while in NYVAC-Gag-Pol-Nef-infected cells Gag-induced virus-like particles (VLPs) are abundant. Electron microscopy revealed that VLPs accumulated with time at the cell surface, with no interference with NYVAC morphogenesis. Both vectors trigger specific innate responses in human cells and show an attenuation profile in immunocompromised adult BALB/c and newborn CD1 mice after intracranial inoculation. Analysis of the immune responses elicited in mice after homologous NYVAC prime/NYVAC boost immunization shows that recombinant viruses induced polyfunctional Env-specific CD4 or Gag-specific CD8 T cell responses. Antibody responses against gp140 and p17/p24 were elicited. Our findings showed important insights into virus-host cell interactions of NYVAC vectors expressing HIV antigens, with the activation of specific immune parameters which will help to unravel potential correlates of protection against HIV in human clinical trials with these vectors.

AB - The generation of vaccines against HIV/AIDS able to induce long-lasting protective immunity remains a major goal in the HIV field. The modest efficacy (31.2%) against HIV infection observed in the RV144 phase III clinical trial highlighted the need for further improvement of HIV vaccine candidates, formulation, and vaccine regimen. In this study, we have generated two novel NYVAC vectors, expressing HIV-1 clade C gp140(ZM96) (NYVAC-gp140) or Gag(ZM96)-Pol-Nef(CN54) (NYVAC-Gag-Pol- Nef), and defined their virological and immunological characteristics in cultured cells and in mice. The insertion of HIV genes does not affect the replication capacity of NYVAC recombinants in primary chicken embryo fibroblast cells, HIV sequences remain stable after multiple passages, and HIV antigens are correctly expressed and released from cells, with Env as a trimer (NYVAC-gp140), while in NYVAC-Gag-Pol-Nef-infected cells Gag-induced virus-like particles (VLPs) are abundant. Electron microscopy revealed that VLPs accumulated with time at the cell surface, with no interference with NYVAC morphogenesis. Both vectors trigger specific innate responses in human cells and show an attenuation profile in immunocompromised adult BALB/c and newborn CD1 mice after intracranial inoculation. Analysis of the immune responses elicited in mice after homologous NYVAC prime/NYVAC boost immunization shows that recombinant viruses induced polyfunctional Env-specific CD4 or Gag-specific CD8 T cell responses. Antibody responses against gp140 and p17/p24 were elicited. Our findings showed important insights into virus-host cell interactions of NYVAC vectors expressing HIV antigens, with the activation of specific immune parameters which will help to unravel potential correlates of protection against HIV in human clinical trials with these vectors.

UR - http://www.scopus.com/inward/record.url?scp=84920855652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920855652&partnerID=8YFLogxK

U2 - 10.1128/JVI.02469-14

DO - 10.1128/JVI.02469-14

M3 - Article

VL - 89

SP - 970

EP - 988

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 2

ER -